Trials / Active Not Recruiting
Active Not RecruitingNCT03634540
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 118 (estimated)
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily.
Conditions
- Renal Cell Carcinoma (RCC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Kidney Cancer
- Renal Cancer
- Renal Cell Carcinoma
- Renal Cell Cancer Metastatic
- Renal Cell Carcinoma Recurrent
- Renal Cell Cancer, Recurrent
- Kidney
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Belzutifan | Belzutifan tablets administered orally. |
| DRUG | Cabozantinib | Cabozantinib tablets administered orally. |
Timeline
- Start date
- 2018-09-27
- Primary completion
- 2027-02-26
- Completion
- 2027-02-26
- First posted
- 2018-08-16
- Last updated
- 2024-12-20
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03634540. Inclusion in this directory is not an endorsement.